Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) Profit After Tax (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Profit After Tax data on record, last reported at -$39.2 million in Q4 2025.

  • For Q4 2025, Profit After Tax fell 3562.78% year-over-year to -$39.2 million; the TTM value through Dec 2025 reached -$143.8 million, down 319.04%, while the annual FY2025 figure was -$143.8 million, 319.04% down from the prior year.
  • Profit After Tax reached -$39.2 million in Q4 2025 per TRDA's latest filing, up from -$44.1 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $55.0 million in Q2 2024 and bottomed at -$44.1 million in Q3 2025.
  • Average Profit After Tax over 4 years is -$11.2 million, with a median of -$19.5 million recorded in 2022.
  • Peak YoY movement for Profit After Tax: skyrocketed 452.05% in 2024, then tumbled 3562.78% in 2025.
  • A 4-year view of Profit After Tax shows it stood at -$24.6 million in 2022, then soared by 61.25% to -$9.5 million in 2023, then skyrocketed by 111.85% to $1.1 million in 2024, then crashed by 3562.78% to -$39.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Profit After Tax were -$39.2 million in Q4 2025, -$44.1 million in Q3 2025, and -$43.1 million in Q2 2025.